NCT06635850Active, not recruitingPhase 2
A Study of Mosliciguat in PH-ILD
A Phase 2, Randomized, Placebo-Controlled Trial to Assess the Efficacy and Safety of Mosliciguat in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease
Source: ClinicalTrials.gov · Last updated 10 Sept 2026
Brief summary (registry, in English)
This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center clinical study to evaluate the safety and efficacy of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD).
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 135 (actual)
- First submitted
- 8 Oct 2024
- Start date
- 29 Oct 2024
- Primary completion date
- 26 May 2026
- Lead sponsor
- Pulmovant, Inc.
- NCT number
- NCT06635850
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 135
- From 29 Oct 2024 to the primary completion date, 26 May 2026
- 78 sites in 20 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Exacerbation of underlying lung disease requiring augmentation of therapy or emergent hospitalization within 28 days prior to randomization.
- Initiation of pulmonary rehabilitation within 28 days prior to randomization.
- Receiving \>10 L/min of oxygen supplementation by any mode of delivery at rest at Baseline.
- Receipt of investigational, or experimental therapy within 42 days OR 5 half-lives prior to randomization.
- Note: Other inclusion and exclusion criteria may apply.
Other illness
- Diagnosis of WHO PH Group 1 (eg. pulmonary arterial hypertension), Group 2 (related to left-heart dysfunction), Group 4 (eg, chronic thromboembolic pulmonary hypertension), or Group 5 (eg, unclassified).
Other
- History or intolerance to or lack of efficacy with mosliciguat or sGC stimulators or activators.
Who the study is looking for
- Participants willing and able to provide informed consent
- Participants with diagnosis of Interstitial Lung Disease (ILD). Diagnosis will be confirmed by a high-resolution computerized tomography (HR-CT) scan showing diffuse parenchymal disease. Eligible diagnosed diseases include one of the following:
- Idiopathic interstitial pneumonia (IIP)
- Chronic hypersensitivity pneumonitis
- ILD associated with connective tissue disease (CTD) with a forced vital capacity (FVC) \< 70% of predicted
- Confirmed pulmonary hypertension (PH) by right heart catheterization (RHC).
- Ability to perform 6MWT ≥100 meters.
Age in the registry: 18 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (78)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.